Why the study?
Does recombinant adenovirus rAdv-P12A3C stimulate systemic and mucosal immune responses compared to inactivated FMDV vaccine in BALB/c mice?
Does recombinant adenovirus rAdv-P12A3C stimulate systemic and mucosal immune responses compared to inactivated FMDV vaccine in BALB/c mice?
The recombinant adenovirus rAdv-P12A3C induces strong systemic and mucosal immune responses against type O FMDV in mice, highlighting its potential as a vaccine.
Foot-and-mouth disease (FMD) is a highly contagious livestock disease of cloven-hoofed animals which causes severe economic losses. The replication-deficient, human adenovirus-vectored FMD vaccine has been proven effective against FMD. However, the role of T-cell-mediated antiviral responses and the mucosae-mediated antiviral responses induced by the adenovirus-vectored FMD vaccine was rarely examined. Here, the capsid protein precursor P1-2A and viral protease 3C of the type O FMDV were expressed in replicative-deficient human adenovirus type 5 vector. BALB/c mice immunized intramuscularly and intraperitoneally with recombinant adenovirus rAdv-P12A3C elicited higher FMDV-specific IgG antibodies, IFN-γ, and IL-4 cytokines than those in mice immunized with inactivated FMDV vaccine. Moreover, BALB/c mice immunized with recombinant adenovirus rAdv-P12A3C by oral and intraocular-nasal immunization induced high FMDV-specific IgA antibodies. These results show that the recombinant adenovirus rAdv-P12A3C could resist FMDV comprehensively. This study highlights the potential of rAdv-P12A3C to serve as a type O FMDV vaccine.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: